This week we’re headed to Basel, Switzerland to join with more than 450 of the world’s #RNA leaders at the RNA Leaders Europe Congress. Looking forward to meeting with RNA experts and sharing our unique approach to RNA modulating therapeutics! Learn more: lsxleaders.com/rna-leaders-wo…

Our clinical team is onsite for the RNA Leaders Europe Congress in Basal, Switzerland to connect with some of the top experts in #RNAtherapeutics. Interested in discussing our platform for antisense oligonucleotide designed to modulate RNA? Send us an email at [email protected]

The HDYO Congress for young adults, families and professionals impacted by #Huntingtonsdisease is taking place this week in Glasgow, Scotland. HDYO supports, educates, and empowers young people impacted by HD around the world. Learn more: en.hdyo.org

The European Huntington Association (@eurohuntington) has put together a fantastic resource for patients and families interested in participating in clinical studies for #Huntingtonsdisease across Europe. Check out their new HD #TrialFinder: hdtrialfinder.net/en/trial-news/

The Annual Ataxia Conference begins today in Las Vegas, NV, and will gather the patient and caregiver community and world-leading #ataxia researchers to discuss updates in research and care.

Today we announced that the first patient has been dosed in our Phase 1/2a clinical study for the treatment of Huntington’s disease (HD), spinocerebellar ataxia type 1 (SCA1) and type 3 (SCA3). Learn more: vicotx.com/vico-therapeut…

Today at the CHDI Foundation’s 18th Annual Huntington’s Disease Therapeutics Conference, our Chief Scientific Officer Nicole Datson, PhD, highlighted preclinical data related to our lead asset in an oral presentation. Find details: vicotx.com/vico-therapeut…

The Huntington’s Disease Association (@HAD_tweeting) offers powerful stories from members of the #HuntingtonsDisease community, providing real perspectives on important topics including diagnosis, disease management and caregiving. Watch: hda.org.uk/getting-help/i…

We’re in New Orleans for the HDSA Annual Convention! Looking forward to meeting with patients & families affected by #Huntingtonsdisease to learn more about their experiences, which play a key role in guiding our efforts to better support them. Learn more hdsa.org/about-hdsa/ann…

This week during the Annual Oligonucletides for CNS Summit, our CSO Nicole Datson PhD will present an overview of our allele-preferential antisense oligonucleotide product candidate being developed for people with #polyglutamine diseases. Find the agenda: oligonucleotides-cns.com

Our Chief Executive Officer Micah Mackison is in Boston for #BIO2023! Connect with us through @IamBIO’s 1x1 Partnering Platform: bio.org/events/bio-int…

Our CEO Micah Mackison is in Munich for #BIOEurope! Join us this week and request a partnering meeting to learn more about our antisense oligonucleotide platform: bit.ly/3Sm2CY8

Our management team will be in San Francisco during the 42nd Annual J.P. Morgan Healthcare Conference, being held from January 8-11. We are available to connect on-site to share more about our work with antisense oligonucleotides focused on genetic neurological disorders. #JPM2024

As we advance important research for multiple polyglutamine disorders, including HD & SCAs, we are committed to sharing the stories of those navigating their own rare journeys. Read Ken’s story, a caregiver for his mom who lives with #HD: rarediseaseday.org/heroes/love-is… #RDD2024

At Vico, our mission is science-driven & patient-focused. Today we join with industry partners & colleagues to advocate for equity for individuals with rare diseases worldwide and their families in recognition of #RareDiseaseDay. Learn more about #RDD2024: rarediseaseday.org

The Huntington’s Disease Association (Huntington's Disease Association) offers powerful stories from members of the #HuntingtonsDisease community, providing real perspectives on important topics including diagnosis, disease management and caregiving. Watch: hda.org.uk/getting-help/i…

Attending #BIO2024? Our executive team is in San Diego - Connect with us through Biotechnology Innovation Organization's 1x1 Partnering Platform: bio.org/events/bio-int…

We are proud to contribute to the advancement of new biomarker analysis options for the benefit of the #Huntingtonsdisease community. Learn more about our recent study published in the Journal of Movement Disorders: pubmed.ncbi.nlm.nih.gov/38379425/

Last month the HDSA celebrated 32 years of Huntington’s Disease Awareness Month with a series of events across the country and an online initiative called #letstalkabouthd. Learn more about their efforts: hdsa.org

We’re looking forward to the @ehdn_news EHDN & Enroll-HD 2024 from Sept 12-14 in Strasbourg, France. On 9/13, our CMO Dr. Scott Schobel will present an update from our ongoing Phase 1/2a clinical trial in #Huntingtonsdisease.